Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:06:28.232Z.
Calculation as of: 2026-10-06T20:06:28.232Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
enGene Holdings Inc.
Market Cap
$120.58M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| enGene Holdings Inc. (ENGN) | $120.58M | N/A |
| Seer, Inc. (SEER)vs › | $120.41M | N/A |
| Cibus, Inc. (CBUS)vs › | $119.84M | N/A |
| BGM Group Ltd. (BGM)vs › | $121.55M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
